CD200R1, a CD11b-interacting protein, inhibits phagocytosis. Credit score: Nature Communications (2025). DOI: 10.1038/s41467-025-60456-3
Immunotherapy has revolutionized most cancers remedy by mobilizing the immune system to assault tumor cells. Main advances, similar to immune checkpoint inhibitors (notably in opposition to the PD-1 protein), have produced spectacular outcomes in opposition to sure kinds of most cancers, together with melanoma and kidney most cancers.
These therapies “take the brakes off” the immune system, growing its skill to detect and destroy most cancers cells. Nevertheless, regardless of their effectiveness, these therapies don’t work for all sufferers or all kinds of most cancers. This realization has prompted researchers all over the world to seek for new therapeutic targets.
Now comes work carried out within the laboratory of Université de Montréal medical professor Dr. André Veillette, director of the molecular oncology analysis unit of the Montreal Medical Analysis Institute (IRCM), in collaboration with scientists from a number of nations, marks a breakthrough within the battle in opposition to treatment-refractory cancers.
Led by Jiaxin Li, a doctoral scholar in Veillette’s lab, the researchers have found a brand new molecule of curiosity known as CD200R1. The discovering is detailed in a examine printed within the journal Nature Communications.
CD200R1 is a protein current on the floor of sure immune cells known as macrophages, which play a key position in detecting and destroying irregular cells. The brand new analysis exhibits that blocking CD200R1 with particular antibodies prompts macrophages, serving to to get rid of blood cancers similar to leukemia and lymphoma in preclinical mouse fashions.
These outcomes pave the best way for a brand new therapeutic strategy for cancers which are immune to present therapies, the scientists consider. The following step for Veillette and his staff is to develop collaborations geared toward proving that this technique also can work in people, which may remodel remedy choices for a lot of sufferers.
Extra info:
Jiaxin Li et al, CD200R1-CD200 checkpoint inhibits phagocytosis otherwise from SIRPα-CD47 to suppress tumor progress, Nature Communications (2025). DOI: 10.1038/s41467-025-60456-3
Offered by
College of Montreal
Quotation:
Blocking CD200R1 protein affords new technique for treatment-resistant blood cancers (2025, June 13)
retrieved 13 June 2025
from https://medicalxpress.com/information/2025-06-blocking-cd200r1-protein-strategy-treatment.html
This doc is topic to copyright. Other than any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
